Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
Compare ATOS Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Atossa Genetics
There are two likely drivers behind the biotech's share price surge.
The sell-off resulted from the company's announcement of phase 2 data for experimental breast cancer drug endoxifen.
The company might announce some extremely good news later this week.
An analyst tracking the stock gets even more bullish on its prospects.
Investors are excited about the potential of the biotech's experimental breast cancer treatment.